Trial · NCT05022563
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Interruption in Index Anticoagulant Treatment | From index date up to treatment interruption, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Analysis population included all eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as one entity, while individual NOAC results discriminated between each NOAC, therefore total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Here, Number Analyzed signifies participants evaluable for specified rows. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Time to Treatment Interruption | From index date up to treatment interruption, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with interruption event;Number Analyzed: participants evaluable for specified rows. | Days | MEDIAN |
| PRIMARY | Number of Participants Who Switched to Another Anticoagulant Therapy | From index date up to treatment switch, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Analysis population included all eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as one entity, while individual NOAC results discriminated between each NOAC, therefore total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Here, Number Analyzed signifies participants evaluable for specified rows. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Time to Treatment Switch | From index date up to treatment switch, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event; Number Analyzed: participants evaluable for specified rows. | Days | MEDIAN |
| PRIMARY | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | From index date up to treatment discontinuation, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Analysis population included all eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as one entity, while individual NOAC results discriminated between each NOAC, therefore total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Here, Number Analyzed signifies participants evaluable for specified rows. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Time to Treatment Discontinuation | From index date up to treatment discontinuation, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC,hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed:participants evaluable for this outcome measure with discontinuation event;Number Analyzed:participants evaluable for specified rows. | Days | MEDIAN |
| PRIMARY | Overall Index Anticoagulant Treatment Duration | From index date up to the earliest of treatment interruption, switch, or discontinuation; during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Analysis population included all eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as one entity, while individual NOAC results discriminated between each NOAC, therefore total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Here, Number Analyzed signifies participants evaluable for specified rows. | Days | MEDIAN |
| PRIMARY | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | Within 3 months of index date, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Analysis population included all eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as one entity, while individual NOAC results discriminated between each NOAC, therefore total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Here, Number Analyzed signifies participants evaluable for specified rows. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | Within 6 months of index date, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Analysis population included all eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as one entity, while individual NOAC results discriminated between each NOAC, therefore total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Here, Number Analyzed signifies participants evaluable for specified rows. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Within 30 days before treatment interruption during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with interruption event;Number Analyzed: participants evaluable for specified rows. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Within 30 days before treatment discontinuation during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC,hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed:participants evaluable for this outcome measure with discontinuation event;Number Analyzed:participants evaluable for specified rows. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05022563/outcomes